Home Tags SMAC-Technology

Tag: SMAC-Technology

Exelixis and BioInvent Establish Exclusive Option and License Agreement to Develop...

Exelixis and Swedish BioInvent International have entered into an option and license agreement focused on the identification and development of novel antibodies for use...

NBE-Therapeutics and Exelixis Sign Agreement to Advance Best-in-class ADCs Against Multiple...

Privately-owned Swiss biotech NBE-Therapeutics and Exelixis, confirmed a new partnership to discover and develop multiple antibody-drug conjugates (ADCs) for applications within oncology and hematology....

SOTIO and NBE-Therapeutics to Develop ‘Second’ Next-Generation Antibody-Drug Conjugate

SOTIO, a biotechnology company leading the efforts of PPF Group, one of the largest investment groups in Central and Eastern Europe, to build a...
Featured Image: Laboratory Glass works. Courtesy: © 2010 - 2018. Fotolia Used with permission.

Steffen Heeger, MD, Ph.D to Lead NBE-Therapeutics’ Clinical iADC Development

Privately-owned Swiss, Basel-based, NBE-Therapeutics has appointed Steffen Heeger MD, Ph.D. as Chief Medical Officer to lead the clinical development of NBE-002, the company's first...

WuXi Biologics and NBE-Therapeutics Collaborate in Development and Manufacturing Partnership

WuXi Biologics, an open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, and Swiss biotech NBE-Therapeutics, developing best-in-class, next-generation...

NBE Therapeutics Receives Additional Series B Financing – Supports Clinical Testing...

Novo Holdings, a Danish private limited liability company wholly owned by the Novo Nordisk Foundation, manages the Foundation's investment assets. Earlier this year, the...

PepTalk 2017: Antibody-drug Conjugates and the Promise of Innovation

ADC or antibody-drug conjugates have recently been at the forefront of cancer research, and according to the experts presenting their latest data during the...

X